Head & Neck Cancers | Specialty

The OncLive Head and Neck Cancer condition center page is a comprehensive resource for clinical news and expert insights on treatment for patients with head and neck cancer. This page features news articles, interviews in written and video format, and podcasts that focus on unmet needs, treatment advances, and ongoing research within head and neck cancer.

Dr. Ciccolini on Dose Levels of Cetuximab in Head and Neck Cancer

April 21st 2017

Joseph Ciccolini, PhD, assistant professor in Pharmocokinetics, Aix-Marseille University, discusses dose levels of cetuximab (Erbitux) in patients with head and neck cancer.

CAR T-Cell Therapy Shows Potential in Head and Neck Cancer

April 19th 2017

Sophie Papa, MD, discusses the early-phase results and the logic behind studying CAR T-cell therapy in solid tumors, such as head and neck cancer.

Researchers Identify Predictors for Distant Metastases in HPV+ Oropharyngeal Cancer

April 13th 2017

Shlomo Koyfman, MD, discusses the findings of a recent study of patients with HPV-positive oropharyngeal cancer treated with cisplatin-based chemoradiotherapy or cetuximab-based bioradiotherapy.

Galectin-1 Inhibition Shows Early Promise in Head and Neck Cancer

April 12th 2017

Dhanya Nambiar, PhD, discusses the role of galectin-1 in the tumor microenvironment, and the potential for targeting this protein in patients with head and neck cancer.

Exploring Residual Concentrations of Agents in Head and Neck Cancer

April 10th 2017

Joseph Ciccolini, PhD, assistant professor in Pharmocokinetics, Aix-Marseille University, discusses investigating the residual concentrations of other agents for the treatment of patients with head and neck cancer.

Pembrolizumab Impresses in Heavily Pretreated Head and Neck Cancer

April 7th 2017

Pembrolizumab has shown durable, clinically significant responses in patients with locally advanced head and neck cancer who are refractory to platinum-based chemotherapy and cetuximab, according to results from the single-arm, phase II KEYNOTE-055 study.

Targeting Galectin-1 With Radiation and Immune Checkpoints in Head and Neck Cancer

April 7th 2017

Dhanya K. Nambiar, PhD, Stanford University, discusses targeting galectin-1 with radiation therapy and immune checkpoint inhibitors in head and neck cancer.

Dr. Papa on CAR T-Cell Therapy for Head and Neck Cancer

April 6th 2017

Sophie Papa, PhD, MBBS, MRCP, King’s College London in the United Kingdom, discusses chimeric antigen receptor (CAR) T-cell therapy for patients with head and neck cancer.

Dr. Ciccolini on Residual Concentrations of Cetuximab in Head and Neck Cancer

April 6th 2017

Joseph Ciccolini, PhD, assistant professor in Pharmocokinetics, Aix-Marseille University, discusses residual concentrations of cetuximab (Erbitux) in patients with head and neck cancer.

Novel RAF Inhibitor Active Across Multiple Tumor Types

April 4th 2017

Treatment with the RAF dimer inhibitor BGB-283 led to clinical benefit for patients with BRAF V600-mutated melanoma, papillary thyroid cancer, and ovarian cancer.

Dr. Papa on Challenges of CAR T-Cell Therapy in Head and Neck Cancer

April 1st 2017

Sophie Papa, PhD, MBBS, MRCP, King’s College London in the United Kingdom, discusses chimeric antigen receptor (CAR) T-cell therapy for patients with head and neck cancer.

Dr. Koyfman on Reirradiation Options for Head and Neck Cancer

March 31st 2017

Shlomo Koyfman, MD, associate staff, radiation oncology, Cleveland Clinic, discusses reirradiation options for patients with head and neck cancer.

Dr. Yarmand Discusses Targeting ATF4 in Thyroid Cancer

March 29th 2017

Rozita Yarmand, PhD, assistant professor, Department of Endocrine Neoplasia and Hormonal Disorders-Research, The University of Texas MD Anderson Cancer Center, discusses targeting ATF4 in medullary thyroid cancer.

Dr. Lorch on the Treatment of Medullary Thyroid Cancer

March 29th 2017

Jochen H. Lorch, MD, director, Thyroid Cancer Center, Dana-Farber Cancer Institute, assistant professor of Medicine, Harvard Medical School, discusses the current treatment landscape of medullary thyroid cancer.

Nivolumab Recommended for EU Approval in Head and Neck Cancer

March 24th 2017

The EMA’s Committee for Medicinal Products for Human Use has recommended approval of nivolumab for the treatment of patients with squamous cell cancer of the head and neck following progression on platinum-based therapy.

Seiwert Summarizes Immunotherapy Advances in Head and Neck Cancer

March 24th 2017

Tanguy Seiwert, MD, discussed advances and next steps with immunotherapy, as well as the overall challenges and goals for treating patients with head and neck cancer.

Dr. Seiwert on Advice With Immunotherapy for Head and Neck Cancer

March 23rd 2017

Tanguy I. Seiwert, MD, assistant professor of Medicine, University of Chicago Medicine, gives advice to community oncologists on administering immunotherapy to patients with head and neck cancer.

Dr. Koyfman on Informing Patients of Reirradiation for Head and Neck Cancer

March 23rd 2017

Shlomo Koyfman, MD, associate staff, Radiation Oncology, Cleveland Clinic, discusses informing patients of reirradiation as a treatment for head and neck cancer.

Dr. Vokes on Biomarker Selection in Head and Neck Cancer

March 22nd 2017

Everett Vokes, MD, John E. Ultmann Professor of Medicine and Radiation Oncology, physician-in-chief, University of Chicago Medical Center, chair, Department of Medicine, University of Chicago Medicine, discusses biomarkers for immunotherapy in head and neck cancer.

Radiation for Chemo-Sensitization: A Phase II Trial of Cetuximab and Docetaxel With Low-Dose Fractionated Radiation for Recurrent Unresectable Locally Advanced Head and Neck Carcinoma

March 19th 2017

This study evaluates low dose radiotherapy in combination with docetaxel and cetuximab in patients with recurrent, unresectable squamous cell carcinoma of the head and neck initially treated with definitive chemo-radiation therapy.